News | August 24, 2021
Lupin launches Luforbec to treat asthma & COPD in UK
It is the first branded generic alternative to Fostair 100/6 pMDI
It is the first branded generic alternative to Fostair 100/6 pMDI
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The data highlights its RSV vaccine cuts hospitalizations in older adults
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Subscribe To Our Newsletter & Stay Updated
